Immunity 101: The Quick Course

Introductory content goes here…

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Mauris placerat ullamcorper sem eu sodales. Praesent suscipit mauris nec augue bibendum, ut consequat massa sodales. Proin et lacus enim. Vivamus vulputate luctus ultrices. Quisque consequat porttitor fringilla. Mauris vitae nulla porttitor, gravida diam et, egestas mauris. Mauris convallis metus at urna rutrum, eget hendrerit metus porttitor. Maecenas posuere lorem rhoncus nisi eleifend mollis. 

Web Tip: This has the potential to change everything and give us freedom like that already enjoyed by those vaccinated who have a normal immune system.

Related Articles

Update to the FDA Fact Sheet for Healthcare Providers: Emergency Use Authorization for Evusheld

On October 3, 2022, the FDA updated the guidance offered to healthcare providers concerning Evusheld (the cocktail of two COVID-19 monoclonal antibodies, tixagevimab, and cilgavimab). Evusheld which is currently the only authorized  Pre-Exposure Prophylaxis (PrEP) against COVID-19 for the immunocompromised, including those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), in whom protection provided by the COVID-19 vaccine is unpredictable and less robust.

New Bivalent COVID-19 Booster Guidance Released by the CDC

As a recap, if you have received either of the mRNA vaccines, namely Pfizer and Moderna, the “primary series” of COVID-19 consists of three full-strength shots for CLL/SLL patients, NOT two (as is the case for those with a healthy immune system).

What Those with CLL/SLL Need to Know About the Latest CDC Guidance for Minimizing the Impact of COVID-19

In the new COVID-19 guidelines released on August 11th, the US Centers for Disease Control and Prevention (CDC) made a change in their recommended infection control measures that are geared more towards increasing the focus on individuals understanding their own risk level for developing severe COVID-19 disease, making a personal decision about what level of risk is acceptable to them, and then giving guidance on how to mitigate those risks.


When appropriate, the CLL Society will be posting updates and background information on the present Coronavirus pandemic focusing on reliable primary sources of information and avoiding most of the news that is not directly from reliable medical experts or government and world health agencies.